National immunity to COVID-19 coronavirus in the United States could be developed by May 2021 as a result of vaccination, said Moncef Slowy, head of Operation Supersonic Speed to prepare for vaccination against COVID-19.
“Our plan is to deliver the vaccines to vaccination sites within 24 hours of approval, I expect it to be possible on the second day after approval – December 11 or 12,” Saloui told CNN.
“Typically, with the 95 percent vaccine effectiveness we have, immunization of about 70 percent of the population will create true collective immunity,” he said. – This is likely to happen sometime in May”.
Saloui’s statement came against the backdrop of news about successful coronavirus vaccine trials by US company Pfizer Inc. and German BioNTech, US company Moderna and Anglo-Swedish AstraZeneca.
On November 20, Pfizer and BioNTech submitted a request for emergency use of COVID-19 vaccine to the Food and Drug Administration (FDA). The request is expected to take at least several weeks to process.
Previously, it was reported that the vaccine developed by Moderna was more than 94% effective. American Pfizer, which developed the vaccine together with German BioNTech, announced 95% efficiency of the product.
As for the vaccine produced by AstraZeneca, it showed an average efficiency of 70% in the UK and Brazil as a result of intermediate tests. At the same time, one of the tried dosage variants gave efficiency of about 90%.
In the U.S. more than 160 thousand new cases of coronavirus are recorded daily, and more than 1000 people among infected people die per day. There are 83,870 patients with COVID-19 in U.S. hospitals.
In total, more than 12 million coronavirus infections have been detected in the country since the beginning of the pandemic, 247.9 thousand people with coronavirus died.